MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Tuesday, October 18, 2011

Genzyme is committed to transforming the landscape of MS treatment


PARIS, Oct 18, 2011 (BUSINESS WIRE) -- Sanofi and its subsidiary Genzyme announced today that more than 20 data presentations from the company's growing multiple sclerosis (MS) portfolio will be showcased at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 2011). Data to be presented will include new results from pivotal Phase III clinical trials of the company's lead investigational candidates for the treatment of relapsing MS, Lemtrada(TM) (alemtuzumab) and Aubagio(TM) (oral teriflunomide), and will be featured in platform and poster presentations.
"Genzyme is committed to transforming the landscape of MS treatment through novel research and development aimed at addressing significant unmet needs for patients with MS," said David Meeker, M.D., Chief Operating Officer, Genzyme. "With Lemtrada(TM) and Aubagio(TM) -- two unique, promising investigational treatments -- we hope to deliver advancement in MS treatment across the patient spectrum."
Following are select abstracts highlighting new data from the Phase III CARE-MS I study (The Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis) and the Phase III TEMSO trial (Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis). Note that data is embargoed until the date and time of the presentation:

 Continue reading



===========================================================
Remain CURRENT with Multiple Sclerosis news  and information 
REGISTER HERE   MS Views and News 
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio Online at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

No comments: